作者
Stephen J Nicholls, Rishi Puri, Todd Anderson, Christie M Ballantyne, Leslie Cho, John JP Kastelein, Wolfgang Koenig, Ransi Somaratne, Helina Kassahun, Jingyuan Yang, Scott M Wasserman, Robert Scott, Imre Ungi, Jakub Podolec, Antonius Oude Ophuis, Jan H Cornel, Marilyn Borgman, Danielle M Brennan, Steven E Nissen
发表日期
2016/12/13
期刊
Jama
卷号
316
期号
22
页码范围
2373-2384
出版商
American Medical Association
简介
Importance
Reducing levels of low-density lipoprotein cholesterol (LDL-C) with intensive statin therapy reduces progression of coronary atherosclerosis in proportion to achieved LDL-C levels. Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors produce incremental LDL-C lowering in statin-treated patients; however, the effects of these drugs on coronary atherosclerosis have not been evaluated.
Objective
To determine the effects of PCSK9 inhibition with evolocumab on progression of coronary atherosclerosis in statin-treated patients.
Design, Setting, and Participants
The GLAGOV multicenter, double-blind, placebo-controlled, randomized clinical trial (enrollment May 3, 2013, to January 12, 2015) conducted at 197 academic and community hospitals in North America, Europe, South America, Asia, Australia, and South Africa and enrolling 968 patients presenting for coronary angiography.
Interventions …
学术搜索中的文章
SJ Nicholls, R Puri, T Anderson, CM Ballantyne, L Cho… - Jama, 2016